Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, Medical University of South Carolina, Charleston, SC.
Division of Hematology and Oncology, Medical University of South Carolina, Charleston, SC.
Chest. 2024 Nov;166(5):1239-1249. doi: 10.1016/j.chest.2024.08.006. Epub 2024 Aug 14.
The initial management of patients with lung cancer is growing more complex in the context of an expanding number of precision medicine treatments. These challenges are accompanied by opportunities to deliver more efficacious and less toxic treatments to patients. Indications for these treatments are also expanding, and patients with lung cancer across multiple stages now require biomarker testing. Given their role in the initial management of patients being diagnosed with lung cancer, pulmonologists must have fundamental knowledge regarding the importance, indications, and implications of biomarker testing across the spectrum of histology and stage. The purpose of this review is to provide fundamental knowledge regarding biomarker testing, its incorporation into the initial diagnostic and staging evaluation, and guidance for working within a multidisciplinary team to achieve timely and comprehensive biomarker testing to direct the use of precision medicine treatments.
在精准医学治疗数量不断增加的背景下，肺癌患者的初始管理变得更加复杂。这些挑战伴随着为患者提供更有效和更少毒性治疗的机会。这些治疗的适应症也在扩大，现在多个阶段的肺癌患者都需要进行生物标志物检测。鉴于生物标志物检测在诊断为肺癌的患者的初始管理中的作用，肺病学家必须具备关于生物标志物检测在整个组织学和分期范围内的重要性、适应症和影响的基本知识。本综述的目的是提供关于生物标志物检测的基本知识，包括将其纳入初始诊断和分期评估，以及指导在多学科团队中工作以实现及时和全面的生物标志物检测，以指导精准医学治疗的使用。
